Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955939 | 0.97 | CYP2C9 (0.42) | KMT2AHPGDMMP8SLC1A2SCN5A | |
| SCHEMBL3955063 | 0.88 | SLC1A2 (0.45) | KMT2AHPGDSLC1A2SCN5ASCN9A | |
| SCHEMBL3954533 | 0.87 | CNR2 (0.39) | ALDH1A1SMN1; SMN2GAACYP2C9CYP2C19 | |
| SCHEMBL27681908 | 0.86 | ADAM17 (0.45) | KMT2AHPGDSCN5ASCN9AMEN1 | |
| SCHEMBL3951075 | 0.86 | CYP2C9 (0.44) | MAPTCYP2C9CYP2C19 | |
| SCHEMBL3960474 | 0.84 | MTOR (0.48) | — | |
| SCHEMBL3954163 | 0.83 | SLC6A2 (0.47) | — | |
| SCHEMBL3955379 | 0.82 | ALDH1A1 (0.43) | KMT2AMMP8MEN1ALDH1A1MAPT | |
| SCHEMBL3960434 | 0.81 | MEN1 (0.46) | KMT2ASCN5ASCN9AMEN1SMN1; SMN2 | |
| SCHEMBL3961565 | 0.80 | LMNA (0.39) | HPGDALDH1A1SMN1; SMN2NPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| CN-1972920-A | Arylalkyl piperazine derivatives for the treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms | WYETH CORP (US) | 2007-05-30 | — | — | CN | disclosed |
| CN-1897946-A | 1- 2' (1, 4'-biperidin-1'-yl)-1- (phenyl) -ethyl cyclohexanol derivatives as monoamine reuptake modulators for the treatment of visomotor symptoms | WYETH CORP (US) | 2007-01-17 | — | — | CN | disclosed |
| CN-1894226-A | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH CORP (US) | 2007-01-10 | — | — | CN | disclosed |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | KMT2A 1752/4885HPGD 724/4885MMP8 809/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | KMT2A 1606/4885HPGD 949/4885MMP8 1366/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | KMT2A 2024/4885HPGD 991/4885MMP8 1202/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | KMT2A 1548/4885HPGD 1128/4885MMP8 1219/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | KMT2A 1875/4885HPGD 82/4885MMP8 988/4885 |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | ASNS, GLS, GYS1 | KMT2A 1886/4885HPGD 1273/4885MMP8 1818/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | KMT2A 1875/4885HPGD 82/4885MMP8 988/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | KMT2A 1015/4885HPGD 686/4885MMP8 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.